Loading...

ACET ADICET BIO INC Operational Disruptions 8-K Filing

DCT

CT

ADICET BIO INC

(ACET)

2023 8-K

Show Summary

Summary

Financial Statements

New Collaboration

Clinical Trial Update

Clinical Trial Update

Loan Termination

Clinical Trials Update

Loan Agreement Amendment

Financial Results

Clinical Trial Update

Clinical Data Release

Strategic Focus Shift

Financial Results

FDA Fast Track Designation ...

FDA Clearance of IND Applic...

Amendment to Stock Option a...

FDA Fast Track Designation ...

Financial Results Announcement

Presentation at ASGCT

Open Market Sales Agreement

Financial Results Announcement

Underwriting Agreement and ...

Corporate Presentation

Corporate Update and Strate...

Resignation of Director

Financial Results Announcement

Financial Results Announcement

Phase 1 Trial Data

Loan Agreement Amendment

Annual Meeting Results

Financial Results Announcement

Financial Results Announcement

No Business Relationship wi...

External Links:

Adicet Bio reports positive data from ongoing Phase 1 trial for ADI-001 in patients with aggressive B-cell non-Hodgkin's lymphoma, with an overall response rate of 71% and complete response rate of 63% across all dose levels.

AI Assistant

ADICET BIO INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.